StockData

Prelude Therapeutics vs ProQR Therapeutics

PRLD and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PRLD and PRQR compare

Prelude Therapeutics grew revenue faster over the last twelve months (220% versus 11.4% for ProQR Therapeutics).

ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −270% at Prelude Therapeutics.

Prelude Therapeutics scores higher on the StockData Score (8 against 7 for ProQR Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPRLDPRQR
Size and price
Market cap$272M–
Share price$3.41$1.18
Change, 1 year126%−45.4%
Change, 5 years−75.6%−83.6%
Beta (5Y)1.402.55
Employees7959
StockData Score
Total score8 (better)7
Valuation score1 (better)0
Growth score12 (better)
Performance score12 (better)
Health score5 (better)3
Dividend score00
Valuation
P/S12.1×–
P/B2.0×–
FCF yield−12.2%–
Fair value$2.15–
Margin of safety−58.4%–
Growth
Revenue growth (TTM)220% (better)11.4%
Profitability
Operating margin−301%−233% (better)
Net margin−270%−229% (better)
FCF margin−148% (better)−273%
Return on equity−57.7%−57.4% (better)
Financial health
Debt / equity0.000.06 (better)
Current ratio4.07 (better)3.49
Altman Z-score−2.61–
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions62.2%57.6%
Held by insiders40.5%37.8%
Insider net buying, 12 months$25.0M (better)$1.3M
Short interest, % of float8.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.